Cargando…

Cariprazine — an Alternative Treatment for Clozapine-resistant Schizophrenia?

Treatment-resistant schizophrenia (TRS) poses a significant therapeutic challenge in psychiatric practice. Clozapine is recognized as a treatment of choice in TRS but is not always effective in alleviating patients’ symptoms. Additionally, clozapine therapy is associated with multiple side effects a...

Descripción completa

Detalles Bibliográficos
Autores principales: Montgomery, Adam, Rogowska, Marianna, Dratcu, Luiz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean College of Neuropsychopharmacology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889903/
https://www.ncbi.nlm.nih.gov/pubmed/36700327
http://dx.doi.org/10.9758/cpn.2023.21.1.202
_version_ 1784880834130477056
author Montgomery, Adam
Rogowska, Marianna
Dratcu, Luiz
author_facet Montgomery, Adam
Rogowska, Marianna
Dratcu, Luiz
author_sort Montgomery, Adam
collection PubMed
description Treatment-resistant schizophrenia (TRS) poses a significant therapeutic challenge in psychiatric practice. Clozapine is recognized as a treatment of choice in TRS but is not always effective in alleviating patients’ symptoms. Additionally, clozapine therapy is associated with multiple side effects and monitoring requirements that often limit its use and negatively affect patients’ compliance with the treatment. Although clozapine augmentation options are available, there is currently no alternative monotherapy proven to be effective in TRS. We present a case of a young man with TRS who failed to respond to appropriate trials of risperidone, aripiprazole and also clozapine, and who experienced impairing adverse effects of clozapine that made further clozapine treatment not only futile but also detrimental to his health. He was successfully treated with cariprazine monotherapy, which culminated in the remission of his both positive and negative symptoms of psychosis as well as in the marked improvement in social functioning. Cariprazine, a newer atypical antipsychotic endowed with a D3-preferring mode of action, may offer a better tolerated and more acceptable treatment option for patients with difficult-to-treat psychotic symptoms.
format Online
Article
Text
id pubmed-9889903
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Korean College of Neuropsychopharmacology
record_format MEDLINE/PubMed
spelling pubmed-98899032023-02-28 Cariprazine — an Alternative Treatment for Clozapine-resistant Schizophrenia? Montgomery, Adam Rogowska, Marianna Dratcu, Luiz Clin Psychopharmacol Neurosci Case Report Treatment-resistant schizophrenia (TRS) poses a significant therapeutic challenge in psychiatric practice. Clozapine is recognized as a treatment of choice in TRS but is not always effective in alleviating patients’ symptoms. Additionally, clozapine therapy is associated with multiple side effects and monitoring requirements that often limit its use and negatively affect patients’ compliance with the treatment. Although clozapine augmentation options are available, there is currently no alternative monotherapy proven to be effective in TRS. We present a case of a young man with TRS who failed to respond to appropriate trials of risperidone, aripiprazole and also clozapine, and who experienced impairing adverse effects of clozapine that made further clozapine treatment not only futile but also detrimental to his health. He was successfully treated with cariprazine monotherapy, which culminated in the remission of his both positive and negative symptoms of psychosis as well as in the marked improvement in social functioning. Cariprazine, a newer atypical antipsychotic endowed with a D3-preferring mode of action, may offer a better tolerated and more acceptable treatment option for patients with difficult-to-treat psychotic symptoms. Korean College of Neuropsychopharmacology 2023-02-28 2023-02-28 /pmc/articles/PMC9889903/ /pubmed/36700327 http://dx.doi.org/10.9758/cpn.2023.21.1.202 Text en Copyright© 2023, Korean College of Neuropsychopharmacology https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Montgomery, Adam
Rogowska, Marianna
Dratcu, Luiz
Cariprazine — an Alternative Treatment for Clozapine-resistant Schizophrenia?
title Cariprazine — an Alternative Treatment for Clozapine-resistant Schizophrenia?
title_full Cariprazine — an Alternative Treatment for Clozapine-resistant Schizophrenia?
title_fullStr Cariprazine — an Alternative Treatment for Clozapine-resistant Schizophrenia?
title_full_unstemmed Cariprazine — an Alternative Treatment for Clozapine-resistant Schizophrenia?
title_short Cariprazine — an Alternative Treatment for Clozapine-resistant Schizophrenia?
title_sort cariprazine — an alternative treatment for clozapine-resistant schizophrenia?
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889903/
https://www.ncbi.nlm.nih.gov/pubmed/36700327
http://dx.doi.org/10.9758/cpn.2023.21.1.202
work_keys_str_mv AT montgomeryadam cariprazineanalternativetreatmentforclozapineresistantschizophrenia
AT rogowskamarianna cariprazineanalternativetreatmentforclozapineresistantschizophrenia
AT dratculuiz cariprazineanalternativetreatmentforclozapineresistantschizophrenia